Voltaiq and NOVONIX Announce Strategic Partnership to Drive Efficiency and Quality in the Battery Industry
HALIFAX, Nova Scotia, Oct. 08, 2024 (GLOBE NEWSWIRE) — Voltaiq, the industry leader in battery quality analytics software, and NOVONIX […]
Axalta Schedules Third-Quarter 2024 Earnings Conference Call
PHILADELPHIA, Oct. 08, 2024 (GLOBE NEWSWIRE) — Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, will release its […]
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) — Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments […]
Enact to Host Third Quarter 2024 Earnings Call November 7th
RALEIGH, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) — Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its third […]
Yoshiharu Announces Strategic Partnership with Xing Sheng Group to Open Flagship Restaurant in Shenyang, China
Agreement with Xing Sheng Group will Bring Yoshiharu Global’s Expanding Cuisine to its First International Location BUENA PARK, Calif., Oct. […]
Runway Growth Finance Corp. Provides Third Quarter 2024 Portfolio Update
Completed Seven Investments in New and Existing Portfolio Companies Representing $75.3 Million in Funded Investments MENLO PARK, Calif., Oct. 08, 2024 (GLOBE […]
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing […]
Seanergy Maritime Mails CEO Letter to Shareholders
Highlights Seanergy’s Value Creating Strategy Underscores Strength of Highly Qualified Seanergy Board of Directors Overseeing Strategy Encourages Shareholders to Vote […]
RDE, Inc. CFO Steve Handy Purchased 25,620 Shares in the Open Market
Average Price per Share of $1.9646 SCHAUMBURG, IL, Oct. 08, 2024 (GLOBE NEWSWIRE) — RDE, Inc. (NASDAQ: GIFT) (the “Company”), […]
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to […]
